Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2382-2393
Open Access | Times Cited: 438

Showing 51-75 of 438 citing articles:

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Bin Song, Ping Yang, Shuyu Zhang
Cancer Communications (2024) Vol. 44, Iss. 3, pp. 297-360
Open Access | Times Cited: 28
A developmental constraint model of cancer cell states and tumor heterogeneity
Ayushi Patel, Itai Yanai
Cell (2024) Vol. 187, Iss. 12, pp. 2907-2918
Closed Access | Times Cited: 26
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Melody Riaud, Jennifer Maxwell, Isabel Soria‐Bretones, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 2, pp. 105-122
Closed Access | Times Cited: 21
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Oleg Timofeev, Philippe Giron, Steffen Lawo, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 19
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Ray Pillai, Sarah E. LeBoeuf, Yuan Hao, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 19
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 727-736
Open Access | Times Cited: 16
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Yixiang Gu, Ruifeng Yang, Yang Zhang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 4
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
Niamh Coleman, Lingzhi Hong, J. Zhang, et al.
ESMO Open (2021) Vol. 6, Iss. 6, pp. 100319-100319
Open Access | Times Cited: 84
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura, Md. Hafiz Uddin, Misako Nagasaka, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 819-835
Open Access | Times Cited: 71
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Rona Yaeger, Riccardo Mezzadra, Jenna Sinopoli, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 41-55
Open Access | Times Cited: 66
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
Hatim Husain, Dean C. Pavlick, Bernard J. Fendler, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 63
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Damien Reita, L. Pabst, Erwan Pencreach, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1321-1321
Open Access | Times Cited: 60
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 3, pp. 383-393
Open Access | Times Cited: 60
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 60
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47
PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 44
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43

Scroll to top